Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest CeQur SA Stories

2014-04-10 08:29:58

- Experienced Medical Device Executive Will Lead Company Through Scale-Up and International Commercialization of PaQ® Insulin Delivery Device - HORW, Switzerland, April 10, 2014 /PRNewswire/ -- CeQur(®) SA, a leader in simple insulin infusion for people with type 2 diabetes, announced the appointment of Douglas Lawrence as chief executive officer, effective immediately. Lawrence replaces CeQur founder James Peterson, who is retiring from the role, but will continue to serve as vice...

2014-03-05 12:26:53

- Study showed ease-of-use, efficacy and high satisfaction among participants who transitioned from multiple daily insulin injections to PaQ device - HORW, Switzerland, March 5, 2014 /PRNewswire/ -- CeQur(®) SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive results from a clinical study of the company's PaQ(® )Insulin Delivery Device were published online today in Diabetes Care, a peer-reviewed journal...

2014-01-08 08:28:16

HORW, Switzerland, Jan. 8, 2014 /PRNewswire/ -- CeQur(®) SA, a leader in simple insulin infusion for people with type 2 diabetes, today announced that the company has been invited to present at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. CeQur management is scheduled to present an overview of the company at the Westin St. Francis Hotel on Wednesday, 15 January, 2014 at 7:30 a.m. PT. The Need for Simple Insulin InfusionThere are currently more than 11 million...

2013-09-09 08:27:53

-- Funding Will Support Broad Scale Commercialization of CeQur PaQ® Insulin Delivery Device- HORW, Switzerland, Sept. 9, 2013 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the closing of a $27 million dollar Series B financing. The financing was led by two new private investors with the participation of all current shareholders, and will support manufacturing scale up for the CeQur PaQ(®) simple...

2013-06-22 12:21:30

- Data presented at the ADA 73rd Scientific Sessions suggest PaQ® may help patients requiring daily insulin injections maintain better glycemic control - HORW, Switzerland, June 22, 2013 /PRNewswire/ -- CeQur(®) SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ(® )Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association...

2013-02-28 12:27:56

- Data presented at international diabetes conference suggest PaQ® device may offer safe, highly satisfying alternative to multiple daily insulin injections - HORW, Switzerland, Feb. 28, 2013 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that initial data from a study of the company's PaQ(® )Insulin Delivery Device were presented today at the 6(th) International Conference on Advanced...

2012-12-11 08:27:36

HORW, Switzerland, Dec. 11, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple delivery devices for diabetes, announced the appointment of Michael Trautmann, MD as medical director for anti-diabetic peptides, effective immediately. Dr. Trautmann has nearly 30 years of experience treating patients and conducting research in the fields of diabetes and endocrinology. From 1993 to 2012, he held senior clinical research positions at Lilly...

2012-11-27 08:28:15

HORW, Switzerland, Nov. 27, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that the PaQ(® )Insulin Delivery Device has received CE Mark approval. PaQ has demonstrated the safety and efficacy required for marketing in Europe. PaQ is a discreet, wearable device that provides three days of consistent, basal insulin delivery as well as easy, on-demand bolus insulin for individuals with type 2 diabetes....

2012-09-26 06:24:29

HORW, Switzerland, Sept. 26, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the completion of a clinical study with the company's PaQ(® )Insulin Delivery Device. The study was designed to evaluate the ability of people with type 2 diabetes to use PaQ in replacing their multiple daily insulin injections required to control their blood sugar. Study endpoints included glycemic control,...

2012-06-05 22:20:52

HORW, Switzerland, June 6, 2012 /PRNewswire/ -- CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced the initiation of a clinical study with the PaQ(® )Insulin Delivery Device. Professor Thomas Pieber, head of the Division of Endocrinology and Metabolism at the University Hospital Graz, Austria, is conducting the study. "This trial is an important step to demonstrate PaQ can be an effective option for the many people with type...